Peptide Knowledge Base · Longevity

FOXO4-DRI: what it is, what the evidence says, and its real status

The senolytic frontier, a peptide built to make worn-out cells self-destruct. Striking in mice, untested in people.

Can you actually get it?

Plain-English verdict: No availability record.

Regulatory status: No regulatory record.

How does FOXO4-DRI work?

A peptide that disrupts the FOXO4–p53 interaction in senescent cells, selectively pushing them into apoptosis.

What it does — and what it does not do

What it does: Cleared senescent cells and improved markers of aging in mouse studies.

What it does not do: It has no human data; the mechanism is powerful and unproven in people.

How honest is the evidence?

Evidence grade D — Animal and lab evidence; human trials still to come.

preclinical only; no human data

A grade measures how much human evidence exists, not whether a molecule is good, safe, or worth your interest. Read our grading methodology for what each grade means.

What we still don't know: No human safety or efficacy data; off-target apoptosis risk is uncharacterized.

WADA status: Not prohibited.

How it is taken

No established human clinical dosing; preclinical.

Who should not take it

Apoptosis-inducing mechanism; not characterized for human safety.

Sources

Baar et al., FOXO4-DRI senolytic (Cell 2017)

Compounded medications are not FDA-approved. We keep two signals separate and never collapse them: whether you can get something, and what the rule currently says. See the live FDA Peptide Tracker for status.

Join the founding list →

Embed this card on your site · free, CC BY 4.0, no key.

Last reviewed Jun 18, 2026 · Peptós.LIFE · Not medical advice.